Stocksigma LogoStocksigma Logo

Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth

Alembic Pharmaceuticals reported a strong performance for Q2 FY27 ended 30th Sep'26, with consolidated revenue rising 36% YoY to Rs 2,603 Cr

Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth

Alembic Pharmaceuticals Ltd 路 Press Release 路 04 Nov 2026, 8:04 pm

Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth Alembic Pharmaceuticals reported a strong performance for Q2 FY27 ended 30th Sep'26, with consolidated revenue rising 36% YoY to Rs 2,603 Cr. EBITDA grew 78% YoY to Rs 578 Cr with a 22% margin, while PAT jumped 81% YoY to Rs 335 Cr. Growth was driven by US Formulations, which surged 77% YoY to Rs 1,003 Cr backed by three new launches. API revenue expanded 39% YoY to Rs 436 Cr, India Formulations grew 14% to Rs 725 Cr, and Ex-US rose 12% to Rs 440 Cr.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements